Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
Date:11/6/2009

ting a 3-month phase 2 study comparing ITCA 650 with twice-daily Byetta® exenatide injections among a larger population of type 2 diabetes patients. The goals of the ITCA 650 program are to enhance the therapeutic effects of exenatide by ensuring patient compliance; provide more consistent, around-the-clock therapeutic drug levels; and reduce side effects, including nausea associated with high peak levels of exenatide exposure observed with repeated injections.

About ITCA 650

ITCA 650 therapy for type 2 diabetes consists of DUROS continuous delivery of exenatide. The DUROS delivery technology comprises the patented DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. The DUROS technology can deliver up to one year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymer encapsulation or albumin fusion, DUROS delivery allows for steady-state drug delivery upon insertion and near immediate withdrawal of therapy, if required. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a twice-daily, self-injection therapy for type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a privately held biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing clinical
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
9. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
10. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health ... disease, announced the hire of Brad Towle ... will be responsible for driving the company,s sales growth, ... experience in healthcare, and specifically his past role in ... to the company at this pivotal time in the ...
(Date:7/28/2014)... San Francisco, California (PRWEB) July 28, 2014 ... reach USD 604.40 billion by 2020, according to a ... scope coupled with the rising demand for effective vaccines ... to patients with unmet medical needs is expected to ... addition, the need to enhance agricultural productivity via the ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2
... Fla. , April 23 Moffitt Cancer Center announces ... for selecting chemotherapy for Non Small Lung Cancer patients.  Each year, ... , , ... ERCC1 levels in cells to predict response to cisplatin-based chemotherapy.   ...
... April 22 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" ... a complaint regarding its proposed merger with Datong Investment Inc ... Circuit for Palm Beach County , State of ... Yanlin Han , a director and Chief Executive Officer ...
... ... role of natural resources in food production. Technologies that grow more from less improve ... (PRWEB) ... has become a founding member of the Sustainability Consortium , an independent group ...
Cached Biology Technology:Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 2Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 4Complaint Filed Regarding Proposed Merger 2Complaint Filed Regarding Proposed Merger 3Complaint Filed Regarding Proposed Merger 4Syngenta joins Sustainability Consortium as Founding Member 2Syngenta joins Sustainability Consortium as Founding Member 3
(Date:7/28/2014)... powerful new tool that can help advance the ... and renewable bioenergy, has been developed by researchers ... BioEnergy Institute (JBEI), a multi-institutional partnership led by ... researchers have developed an assay that enables scientists ... sugar transporters, critical components in the biosynthesis of ...
(Date:7/28/2014)... The Wyss Institute for Biologically Inspired Engineering at ... technology will be commercialized by a newly formed ... cosmetic, and personalized medicine products. The ... Office of Technology Development (OTD) and the start-up ... Institute,s automated human Organs-on-Chips platform. , "This ...
(Date:7/27/2014)... have survived the asteroid strike that wiped them out ... in history, scientists say. , A fresh study using ... palaeontologists to build a new narrative of the prehistoric ... found that in the few million years before a ... experiencing environmental upheaval. This included extensive volcanic activity, changing ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Dinosaurs fell victim to perfect storm of events, study shows 2
... is part of a research team breaking new ground in ... $2.5 million grant from the National Institutes of Health, the ... for Xerostomia, or dry mouth, an inevitable consequence of radiation ... project is a collaborative effort between researchers at Rice University, ...
... Ore. Many studies have found that high levels of ... poor fitness and reduced chance of survival but recent ... be a good thing, often the difference between life and ... glucocorticoid hormones, which are part of the natural response to ...
... have identified 38 new genetic regions that are associated with ... total number of genetic regions associated with glucose and insulin ... type 2 diabetes. The researchers used a technology ... to follow-up on genome-wide association results. This technology, Metabochip, was ...
Cached Biology News:UD partner in NIH research project to produce artificial salivary glands 2UD partner in NIH research project to produce artificial salivary glands 3For young birds, getting stressed out can be a good thing 2Metabolic MAGIC 2Metabolic MAGIC 3
... These versatile vacuum cups provide ... smooth, curved, or irregular surfaces. ,PFG: ... Short Bellows cup ,PCG: Multiple Bellows ... typically from 25 to 200 mm ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... the smallest electronic pressure controller available measuring ... configured this unit specifically for the analytical ... in carrier gas flow control, microfluidic flow ... hydro-dynamic focusing, the OEM-EPC offers external pressure ...
Biology Products: